Related Experiment Videos
Simultaneous therapy with antiplatelet and anticoagulant drugs in symptomatic cardiovascular disease
Insights
Aspirin and warfarin combination therapy effectively treated patients with advanced atherosclerosis complications, leading to symptom resolution. Careful monitoring is crucial due to potential thrombotic and hemorrhagic complications.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Advanced atherosclerosis presents significant challenges in cardiovascular and vascular disease management.
- Symptomatic patients often have multiple risk factors, including familial hyperlipoproteinemia.
Purpose of the Study:
- To evaluate the efficacy and safety of simultaneous aspirin and warfarin therapy.
- To assess this combination as a therapeutic alternative for refractory atherosclerosis complications.
Main Methods:
- Retrospective analysis of 20 patients with symptomatic atherosclerotic or rheumatic heart/vascular disease.
- Average treatment duration of 5.8 years with aspirin and warfarin concurrently.
Main Results:
- All 20 patients achieved asymptomatic status or marked clinical improvement.
- Complications occurred in 7 patients (thrombotic/hemorrhagic), including one death from intracranial bleeding.
- Two additional patients died suddenly, likely from acute myocardial ischemia.
Conclusions:
- Combined aspirin and warfarin may be a viable therapeutic option for advanced atherosclerosis when other treatments fail.
- Close monitoring of prothrombin times and clinical status is essential due to potential risks.
Abstract:
Twenty of approximately 1000 patients attending the arteriosclerosis clinic at MIT during a 13 year period were treated simultaneously with aspirin and warfarin for symptomatic atherosclerotic (19) or rheumatic (1) heart or vascular disease. The average duration of therapy was 5.8 years. Thirteen patients suffered from familial hyperlipoproteinemia; only one patient had none of the major risk factors for arteriosclerosis. Refractory symptoms were related to the central nervous system in 13, peripheral vascular system in 5 and the heart in 2. All twenty patients became asymptomatic or showed marked clinical improvement on aspirin plus warfarin therapy. While on this therapy, complications, both thrombotic and hemorrhagic, occurred in 7 of the 20 patients (graft embolus in 1, and bleeding in 6; with one death as a result of intracranial bleeding) and sudden death, probably from acute myocardial ischemia, in a further 2 patients. We conclude that when alternative therapies are impossible or have proven to be of no avail in patients suffering from the complications of advanced atherosclerosis, the simultaneous administration of aspirin and warfarin may be a therapeutic alternative, although very close and careful followup of the patients' prothrombin times and clinical status is essential.